XML 28 R4.htm IDEA: XBRL DOCUMENT v3.24.1.u1
CONSOLIDATED CONDENSED STATEMENTS OF OPERATIONS - USD ($)
shares in Millions, $ in Millions
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Income Statement [Abstract]    
Net sales $ 1,598.2 $ 1,459.6
Cost of sales 385.6 329.5
Gross profit 1,212.6 1,130.1
Selling, general, and administrative expenses 489.7 436.3
Research and development expenses 285.2 261.2
Intellectual property agreement and certain litigation expenses (Note 3) 8.9 43.5
Change in fair value of contingent consideration liabilities (Note 7) 0.0 0.7
Separation costs (Note 4) 41.3 0.0
Operating income, net 387.5 388.4
Interest income, net (16.5) (8.6)
Other income, net (5.4) (1.6)
Income before provision for income taxes 409.4 398.6
Provision for income taxes 58.4 58.1
Net income 351.0 340.5
Net loss attributable to noncontrolling interest (0.9) 0.0
Net income attributable to Edwards Lifesciences Corporation $ 351.9 $ 340.5
Earnings per share:    
Basic (in dollars per share) $ 0.58 $ 0.56
Diluted (in dollars per share) $ 0.58 $ 0.56
Weighted-average number of common shares outstanding:    
Basic (in shares) 601.6 607.5
Diluted (in shares) 604.1 610.9